Clinical trial
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
NCT02974153 is registered in ClinicalTrials.gov with Alder Biopharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
- Lead sponsor
- Alder Biopharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2016
- Completion date
- April 30, 2018
- Enrollment
- 1,121 (actual)
- Sites
- 144
Conditions
As the registry lists them; a condition with its own page is linked.